News
UCB Acquires Engage Therapeutics for $125M
UCB announced the acquisition of Engage Therapeutics, Inc., a clinical-stage pharmaceutical company developing Staccato®Alprazolam for the rapid termination of an active epileptic seizure, for US$ 125 million in cash (subject to certain adjustments) and up to US$ 145 million...
News
Lonza to Host New Webinar – “The Compendia are ready. Are you? A More Sustainable Future for Endotoxin Testing”
On 16 June, Lonza will host a free 60-minute webinar on the latest regulatory developments surrounding the use of the recombinant Factor C (rFC) assay for endotoxin detection in parenteral pharmaceuticals and implantable medical devices. During the webinar, Allen...
News
Albumedix Announces Appointment of Gregor Kawaletz as Chief Commercial Officer
Albumedix Ltd., the world leader in recombinant human albumin (rAlb), announced the strengthening of its Executive Leadership with the appointment of Gregor Kawaletz as Chief Commercial Officer, as of June 1st, 2020. This announcement follows the recent appointment of...
News
Sygnature expands capabilities with acquisition of Alderley Oncology
Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is further strengthening its oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo...
News
Messe Frankfurt to focus on highlighting strong anti-counterfeiting measures in wake of Covid-19
As demand for medical supplies soars worldwide in the fight against Covid-19, there is a parallel risk of substandard and counterfeit medicines in the global market. With India being one of the world's largest producers of medical supplies, there...
News
WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit
WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced Therapies business unit, WuXi AppTec’s cell and gene therapy Contract...
News
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. announced an expansion of their existing collaboration to provide Regeneron with rights to develop products for additional in vivo CRISPR/Cas9-based therapeutic targets and for the companies to jointly develop potential products for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read